Raymond James Financial
MDGL icon

Raymond James Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Raymond James Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Sell
19,305
-47,224
-71% -$24.2M ﹤0.01% 2124
2026
Q1 		$34.1M Sell
66,529
-195
-0.3% -$93.2K 0.01% 1105
2025
Q4 		$38.9M Sell
66,724
-3,860
-5% -$1.97M 0.01% 984
2025
Q3 		$32.4M Buy
70,584
+15,651
+28% +$5.84M 0.01% 1081
2025
Q2 		$16.6M Buy
54,933
+1,017
+2% +$303K 0.01% 1502
2025
Q1 		$17.9M Buy
53,916
+70
+0.1% +$23K 0.01% 1389
2024
Q4 		$16.6M Buy
+53,846
New +$15.1M 0.01% 1456

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial's MDGL Position: Q2 2026 in Review

Raymond James Financial reduced its Madrigal Pharmaceuticals (MDGL) stake by 71% in Q2 2026, selling an estimated $24.2M and leaving 19,305 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2124.

Raymond James Financial first reported a position in MDGL in Q4 2024 and has held it in 7 quarters since. The position peaked at $38.9M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Raymond James Financial held 19,305 shares of Madrigal Pharmaceuticals worth $10.4M as of Q2 2026.
  • Raymond James Financial sold 47,224 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $24.2M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2124 holding.
  • Raymond James Financial first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Madrigal Pharmaceuticals position peaked at $38.9M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.